I was re-reading BioExec's excellent post of 21 February and a particular point resonated with a reply I received from RH in relation to a series of questions. First of all BioExec said;
"So what are the other problems with CPP use, well they deliver to almost all cells (of course it varies a bit and also where the cargo is delivered varies a bit) but basically you get off-target effects (bad). Now they chose Myc, my guess in part, because Omomyc, surprisingly appears to have no effect if it gets into normal cells. If true, and it looks like it is, that would be great, dont have to worry about the side effects from off-target. This doesnt alleviate the sink effect, but at least if it is accumulating in other cells it shouldnt do anything bad."
RH was discussing the fact that there are no therapies in clinical trials which directly target Myc although there are several drugs in development which indirectly act upon Myc via upstream signalling pathways. The problem with indirectly targeting Myc is that multiple pathways are modulated by the drug not just Myc, leading to off-target activity and unintended side effects. RH makes the point that off-target activity is a key reason for failure in clinical trials.
Myc has proven to be undruggable. The kicker, however, is that if it can be directly targeted one can overcome the off-target effects (bad). The flip side for successful intervention is therapeutic leverage towards a clinical trial.
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)